(Q41113849)

26 September 2017

1 reference

title

Enantioselective assays in comparative bioavailability studies of racemic drug formulations: nice to know or need to know? (English)

1 reference

26 September 2017

1 reference

1 reference

Karim A

1

1 reference

26 September 2017

publication date

1 June 1996

1 reference

The Journal of Clinical Pharmacology

26 September 2017

published in

1 reference

26 September 2017

volume

36

1 reference

26 September 2017

issue

6

1 reference

26 September 2017

page(s)

490-499

1 reference

Bias in pharmacokinetics and clinical pharmacology.

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Stereoselective drug disposition: potential for misinterpretation of drug disposition data.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Chirality. Clinical pharmacokinetic and pharmacodynamic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Enantiomer specific pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Stereoselectivity in clinical pharmacokinetics and drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Enantioselective pharmacodynamics and pharmacokinetics of chiral non-steroidal anti-inflammatory drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

The importance of stereochemistry in drug action and disposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Stereoselective and isozyme-selective drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Chirality in new drug development. Clinical pharmacokinetic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Racemates or enantiomers: regulatory approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

From controversy to resolution: bioequivalency of racemic drugs--a symposium on the dynamics, kinetics, bioequivalency, and analytical aspects of stereochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Bioequivalence of racemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Bioequivalence requirements for generic products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Pharmacokinetics of ketoprofen enantiomers after different doses of the racemate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Plasma levels of (+) and (-)-propranolol and 4-hydroxypropranolol after administration of racemic (+/-)-propranolol in man

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Stereoselective first-pass metabolism of highly cleared drugs: studies of the bioavailability of L- and D-verapamil examined with a stable isotope technique

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Aging of women alters S-verapamil pharmacokinetics and pharmacodynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Verapamil stereoisomerism: enantiomeric ratios in plasma dependent on peak concentrations, oral input rate, or both.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Pharmacokinetics of ketoprofen enantiomers in healthy subjects following single and multiple doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Clinical pharmacokinetics of ketoprofen and its enantiomers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Enantioselective versus non-enantioselective assays in comparative bioavailability studies with racemic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Stereoselective delivery and actions of beta receptor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

The metabolic chiral inversion and dispositional enantioselectivity of the 2-arylpropionic acids and their biological consequences

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Application of a stereospecific high-performance liquid chromatography assay to a pharmacokinetic study of etodolac enantiomers in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Nonlinear pharmacokinetics: clinical Implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Clinical pharmacology of the stereoisomers of leucovorin during repeated oral dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Pharmacokinetic evaluation in man of terbutaline given as separate enantiomers and as the racemate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

Active Transport of L-Dopa in the Intestine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FJ.1552-4604.1996.TB05038.X

10.1002/J.1552-4604.1996.TB05038.X

21 January 2018

Identifiers

DOI

1 reference

26 September 2017

1 reference